Key Takeaways
- Pricing pressure persists, but the floor is near: Revenue fell YoY on a 7-8% price decline, yet the QoQ rate variance narrowed to just 0.5%, signaling stabilization at the composite level.
- Salicylic acid is the make-or-break swing factor: The new plant is running at only ~100 tons/month against 1,800 tons/month capacity; management targets 200-300 tons/month by November, and a successful ramp-up is the single largest lever to break out of the INR65-70 crores EBITDA range.
- Regulatory unlocks are stacking up, but revenue is 6 months away: The API facility cleared a surprise US FDA audit with 7 observations and a strong CAPA submitted, while the oncology block and OSD facility received US FDA and UK MHRA approvals; commercial supply from these wins is unlikely to show a material financial impact in the first 6 months.
- Guidance reset anchors expectations lower: The 2-3 year revenue potential was revised down from INR4,200-4,500 crores to INR3,500-4,000 crores, reflecting the reality of current API prices, while FY25 sales are expected to be flattish YoY.
- What to watch next quarter: Whether salicylic acid production hits the 200-300 tons/month target in November, the pace of export demand recovery, and any further price declines in antibiotics beyond October.
Pricing & Demand Environment
- The price damage is done, but not fully healed: Selling prices have fallen every quarter for 12-15 months, driven primarily by raw material cost declines and secondarily by Q1 overstocking, weak domestic and export demand, and elections in export geographies. The QoQ composite rate variance is now just 0.5%, but certain antibiotics and one antifungal saw further declines in October.
- YoY comparisons will improve mechanically: Last year's price correction started in September and continued through January, so H2 FY25 YoY rate variance is expected to narrow to low single digits even if absolute prices do not recover.
- Export demand is stirring, not yet running: Management noted a little uptick in export inquiries and some demand improvement, but the first two quarters had lacklustre demand that prevented volume growth from offsetting the negative rate variance.
- Spec-Chem weakness is a small but real drag: Lower offtake of campaign-based products from a few MNCs due to low demand cost 0.25% to 0.3% in gross margin at the company level this quarter.
Adhish Patil: "So it has more or less stabilized. However, I would like to point out that in certain antibiotic products, we are still seeing a slight decline in selling prices as we start the current December quarter."
Salicylic Acid: The Turnaround Bet
- The plant is running, but far from capacity: Production started at the beginning of FY25 and is currently at roughly 100 tons per month against a total capacity of 1,800 metric tons per month. The ramp-up will be phased throughout FY25 and FY26.
- November is the critical milestone: October saw some ramp-up through experiments; management is internally targeting at least 200 to 300 tons per month in November, and once the steaming issue is resolved, the ramp-up is expected to be quite fast.
- The derivatives hedge is real: Because of the price fall in salicylic acid driven by dumping from China, salicylates (methyl salicylate, acetylsalicylic, hexyl salicylate, benzyl salicylate) are looking more attractive. Management is planning capacity for salicylates so that if salicylic acid is unprofitable, salicylates will definitely make more money.
- This is the project that unlocks the EBITDA range: The company has been stuck in the INR65-70 crores EBITDA range for 9-10 quarters; management expects to move out of this zone from Q4 onwards, with the salicylic acid ramp-up and resulting operating leverage as the primary driver.
Adhish Patil: "So we are thinking of going ahead to have capacity for salicylates in case we are not able to make money in salicylic acid, then definitely salicylates will definitely make more money."
Regulatory Milestones & Formulation Business
- US FDA surprise audit cleared with confidence: A 7-8 day surprise audit at the API facility in September resulted in 7 observations, with no repeat observations from prior audits. The company submitted a strong CAPA response within 15 working days with help from US-based consultants. The FDA inspector indicated that a very strong CAPA cover within 15 days might get it through.
- Two formulation approvals are now in hand: The oncology block in Baddi received US FDA approval (audit completed end of Q1), and the OSD facility received UK MHRA approval (audit completed beginning of Q2). Both audits caused lesser output production from the formulation plants during the quarter.
- Revenue from regulatory wins is a 6-month story: In the regulatory market, getting approval and starting commercial supply takes around 5 to 6 months once initiated by customer quality teams. Old projects already in the pipeline should start in 6 months' time, while new projects will take longer. The first 6 months are very unlikely to show significant financial impact.
- Europe may improve before the US: Even before US business kicks in, European business will show signs of improvement from the OSD plant because the US FDA hurdle has been resolved. The formulation business has a strong order book of more than $12 million and will pick up in the coming 2-3 quarters.
- US and Europe are higher-realization markets: Management confirmed these markets carry definitely higher, much higher realizations, and noted that the plants serving them are currently underutilized, so the operating leverage potential is also higher.
Adhish Patil: "In fact, in the closing meeting we did ask him, what they feel about the API facility. So he was like, it is like any other API facility, any other API facility. So that way he was not negative about it. But nevertheless, they did tell us that you give a very strong CAPA cover for this within 15 days, and it might get through."
Capex Cycle & Capacity Build-Out
- The INR600 crores capex cycle is nearly complete: Most of the capex embarked on starting FY22 will be done by this year itself. Total capex for FY25 is anticipated at roughly INR200 crores, funded mainly through internal accruals and partly through term loans.
- Saykha greenfield is imminent: The specialty chemicals plant is complete; trials have started for the derivative plant, and the main plant will start trials in November after Diwali, by mid-to-end of November. CWIP capitalization is expected mostly by the December quarter, at most Q4, but this year itself. The plant might have potential to add around INR40 crores to EBITDA.
- Anti-diarrheal and metformin capacity are next: Steps for anti-diarrheal capacity (Metronidazole) are already taken and will come online in a month's time with a CTO already received. Metformin scale-up to 1,700-1,800 tons is planned in the very short term, but requires an amended environmental clearance and a land parcel currently delayed for governmental reasons; ultimate potential is about 2,000 to 3,000 tons per month.
- Derma facility is a near-term fix: The derma facility is not optimally working right now; once production is streamlined by November, the negative impact will go away, the facility will reach breakeven, and at 700-800 tons per month it will turn profitable, adding INR6 crores plus additional profit.
- Long-term expansion is still on paper: Plans for growth beyond the INR3,500-4,000 crores turnover level are still being finalized; products have yet to be selected and will then be launched in existing land parcels.
Segment & Product Dynamics
- API segment has room to run: Current utilization is roughly 78% for the September quarter, with scope to increase. Growth drivers include new capacity for antidiarrheal products, the addition of Fluconazole to the antifungal basket, and higher utilization of current capacities.
- Metformin is a commitment play: In a bad business cycle, other products have done better than metformin, but management is committed to the product, citing that the anti-diabetic segment should be a growing product on a steady state and its future is better than the rest of the products.
- Formulation output was temporarily suppressed: Two major regulatory audits during the quarter caused changes and lesser output production from the formulation plants, creating a short-term drag that should reverse as the plants return to normal operations.
- Salicylic acid defies clean classification: The product sits in a mixed category because it serves as both an API and an intermediate for manufacturing aspirin, complicating segment-level analysis.
Adhish Patil: "Even now, it is growing at a good pace. So we are committed to this particular product. So we think the future is better than rest of the products for this particular product."
Margins & Profitability
- The EBITDA range has been sticky for too long: The company has been in the INR65-70 crores EBITDA range for 9-10 quarters. Management expects to move out of this zone from Q4 onwards as multiple initiatives converge.
- Gross margin took a small Spec-Chem hit: Lower offtake of campaign-based products from a few MNCs cost 0.25% to 0.3% in gross margin at the company level this quarter.
- The long-term margin target is intact: Efforts will always be to reach around 14.5% to 15.5% EBITDA in the long term, with a target of around 15% to 15.5%.
- The December quarter is a transition period: Management cautioned that the current December quarter may not look very good but will bring a lot of clarity on how things shape up in the future, as many things are happening simultaneously.
Adhish Patil: "Probably may not look very good. I'm not saying -- but it will bring a lot of clarity to the table that how things will shape up in the future."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Salicylic acid production ramp-up | Reach 200-300 tons per month | November 2024 (internally targeted) |
| Salicylic acid capacity ramp-up | Ramp to 300-plus tons per month | By end of December quarter (Q3 FY25) |
| Derma facility breakeven | Streamline production, eliminate negative impact | November 2024 |
| Derma facility profitability | Turn profitable at 700-800 tons per month | Once throughput achieved (no date) |
| Saykha greenfield CWIP capitalization | Plant to go online, capitalize CWIP | December quarter (Q3 FY25), at max Q4 FY25 |
| Total FY25 capex | Roughly INR200 crores | Full year FY25 |
| Move out of INR65-70 crores EBITDA range | Exit the 9-10 quarter range | From Q4 FY25 onwards |
| Revenue potential (revised guidance) | INR3,500-4,000 crores | 2-3 year timeline from now |
| US FDA regulatory outcome | Await response to CAPA submission | Submitted within 15 working days of audit; timeline for agency response not specified |
| Old formulation projects commercial supply | Start commercial supply | 6 months' time |
| Formulation business pickup | Pick up on strong order book of more than $12 million | Coming 2-3 quarters |
| Long-term EBITDA margin target | 15% to 15.5% | Long term (no specific date) |
Key Metrics
| Metric | Q2 FY25 |
|---|---|
| Standalone revenue | ₹543.1 cr, down 6% YoY from ₹577.5 cr |
| Domestic/export mix | 66% domestic, 34% export |
| EBITDA | ₹68.5 cr, margin at 11.5% |
| PAT | ₹35 cr |
| Formulation segment revenue | ₹65.6 cr, exports contribution 53% |
| H1 FY25 formulation revenue | ₹136.6 cr |
| API segment utilization | 78% for the September quarter |
| YoY price variance (API) | negative 7%–8% |
| QoQ price variance (composite) | negative 0.5% versus June quarter |
| Salicylic Acid production | ~100 tons per month, capacity of 1,800 metric tons per month |
| Salicylic Acid PBT impact | ₹5.5 cr negative impact at bottom line from lower production and unabsorbed overheads |
| Metformin sales volume | more than 1,000–1,200 tons per month |
| Metformin capacity | 1,350–1,400 tons per month |
| H1 FY25 capex incurred | ~₹90 cr |
| Full-year FY25 capex guidance | ~₹200 cr, through internal accruals and partly term loans |
| Outstanding CWIP | slightly less than ₹300 cr, expected to transfer to fixed assets by Q3 or Q4 FY25 |
| Derma facility depreciation and interest hit | ₹3.5 cr–₹4 cr per quarter |
| Formulation export order book | more than $12 million |
| US FDA audit observations | 7 observations, response submitted within 15 working days |
| Long-term EBITDA target | 15%–15.5% |
| Revised revenue potential guidance | ₹3,500 cr–₹4,000 cr by FY27, down from earlier ₹4,200 cr–₹4,500 cr |
| Standalone revenue potential at current pricing and capacity | ₹2,750 cr (API plus spec chem, excluding greenfield projects) |
| Buyback completed | 665,000 equity shares at ₹900 per share, face value ₹10 each |